CTRE Stock Analysis: CareTrust REIT | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 8.514m USD | 12M Return: 12.7% | US14174T1079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.6M
EPS Trend: 98.8%
Qual. Beats: 0
Rev. Trend: 94.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CareTrust REIT, Inc. (NYSE: CTRE) is a Maryland-incorporated real estate investment trust established in 2013 and publicly listed since its 2014 IPO. The company operates as a self-administered REIT focused on owning, acquiring, developing, and leasing skilled nursing facilities, seniors housing, and other healthcare-related properties across the United States and the United Kingdom.
CareTrust primarily generates revenue through long-term net-lease agreements with healthcare operators, a structure in which tenants are typically responsible for property-level expenses such as taxes, insurance, and maintenance in addition to base rent. As a healthcare REIT, the company operates within a sector that invests in real estate tied to medical and senior care services, serving an aging demographic with growing demand for skilled nursing and assisted living facilities.
- Interest rate cuts compress borrowing costs and boost yields
- Skilled nursing operator concentration risks rental income stability
- Acquisition pipeline drives portfolio expansion and revenue growth
| Net Income: 355.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.81 > 1.0 |
| NWC/Revenue: 19.16% < 20% (prev 102.9%; Δ -83.74% < -1%) |
| CFO/TA 0.08 > 3% & CFO 447.0m > Net Income 355.4m |
| Net Debt (1.16b) to EBITDA (523.3m): 2.21 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (234.2m) vs 12m ago 21.46% < -2% |
| Gross Margin: 76.03% > 18% (prev 94.92%; Δ -18.88% > 0.5%) |
| Asset Turnover: 10.27% > 50% (prev 5.95%; Δ 4.32% > 0%) |
| Interest Coverage Ratio: 8.19 > 6 (EBIT TTM 414.3m / Interest Expense TTM 50.6m) |
| A: 0.02 (Total Current Assets 625.1m - Total Current Liabilities 520.9m) / Total Assets 5.93b |
| B: -0.08 (Retained Earnings -503.2m / Total Assets 5.93b) |
| C: 0.08 (EBIT TTM 414.3m / Avg Total Assets 5.29b) |
| D: 3.17 (Book Value of Equity 4.49b / Total Liabilities 1.42b) |
| Altman-Z'' = 3.70 = AA |
As of October 17, 2026, the stock is trading at USD 36.55 with a total of 2,161,438 shares traded. Over the past week, the price has changed by +1.44%, over one month by -2.75%, over three months by -11.99% and over the past year by +12.65%.
Current recommended Stop Loss: 35.30 (which is 3.4% or 1.8 ATR below the current price).
CareTrust REIT has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy CTRE.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.8 | 22.5% |
P/E Trailing = 22.5188
P/E Forward = 21.322
P/S = 14.8987
P/B = 1.9555
P/EG = 1.26
Revenue TTM = 543.4m USD
EBIT TTM = 414.3m USD
EBITDA TTM = 523.3m USD
Long Term Debt = 895.1m USD (from longTermDebt, last quarter)
Short Term Debt = 310.0m USD (from shortTermDebt, last quarter)
Debt = 1.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.16b USD (calculated: Debt 1.21b - CCE 49.3m)
Enterprise Value = 9.67b USD (8.51b + Debt 1.21b - CCE 49.3m)
Interest Coverage Ratio = 8.19 (Ebit TTM 414.3m / Interest Expense TTM 50.6m)
EV/FCF = 22.42x (Enterprise Value 9.67b / FCF TTM 431.4m)
FCF Yield = 4.46% (FCF TTM 431.4m / Enterprise Value 9.67b)
FCF Margin = 79.37% (FCF TTM 431.4m / Revenue TTM 543.4m)
Net Margin = 65.40% (Net Income TTM 355.4m / Revenue TTM 543.4m)
Gross Margin = 76.03% ((Revenue TTM 543.4m - Cost of Revenue TTM 130.2m) / Revenue TTM)
Gross Margin QoQ = 93.45% (prev 56.85%)
Tobins Q-Ratio = 1.63 (Enterprise Value 9.67b / Total Assets 5.93b)
Interest Expense / Debt = 4.20% (Interest Expense 50.6m / Debt 1.21b)
Taxrate = 2.41% (8.78m / 363.7m)
NOPAT = 404.3m (EBIT 414.3m * (1 - 2.41%))
Current Ratio = 1.20 (Total Current Assets 625.1m / Total Current Liabilities 520.9m)
Debt / Equity = 0.27 (Debt 1.21b / totalStockholderEquity, last quarter 4.49b)
Debt / EBITDA = 2.21 (Net Debt 1.16b / EBITDA 523.3m)
Debt / FCF = 2.68 (Net Debt 1.16b / FCF TTM 431.4m)
Total Stockholder Equity = 4.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.71% (Net Income 355.4m / Total Assets 5.93b)
RoE = 8.54% (Net Income TTM 355.4m / Total Stockholder Equity 4.16b)
RoCE = 8.19% (EBIT 414.3m / Capital Employed (Equity 4.16b + L.T.Debt 895.1m))
RoIC = 7.10% (NOPAT 404.3m / Invested Capital 5.69b)
WACC = 5.54% (E(8.51b)/V(9.72b) * Re(5.74%) + D(1.21b)/V(9.72b) * Rd(4.20%) * (1-Tc(0.02)))
Discount Rate = 5.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.06 | Cagr: 28.52%
[DCF] Terminal Value 77.97% ; FCFF base≈379.2m ; Y1≈434.7m ; Y5≈639.8m
[DCF] Fair Price = 35.86 (EV 9.63b - Net Debt 1.16b = Equity 8.47b / Shares 236.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.76 | EPS CAGR: 25.54% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.37 | Revenue CAGR: 45.01% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.44 | Chg30d=+3.57% | Revisions=+40% | Analysts=3
EPS current Year (2026-12-31): EPS=1.77 | Chg30d=+2.60% | Revisions=+0% | GrowthEPS=+30.8% | GrowthRev=+30.2%
EPS next Year (2027-12-31): EPS=1.76 | Chg30d=-0.11% | Revisions=+40% | GrowthEPS=-0.6% | GrowthRev=+29.4%
[Analyst] Revisions Ratio: +44% (up=5, down=1)